Current Report Filing (8-k)

  

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 19, 2021

 

Vycor Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware		001-34932		20-3369218
(State or Other Jurisdiction of Incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

 

951 Broken Sound Parkway, Suite 320, Boca Raton, FL		33487
(Address of Principal Executive Offices)		(Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class		Trading Symbol		Name of Each Exchange on which registered
Common Stock, par value $0.0001		VYCO		OTCQB

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

TABLE OF CONTENTS

 

Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers
SIGNATURES

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers

 

On March 19, 2021 the Company’s Board of Directors accepted the tendered resignations of Steven Girgenti and Lowell Rush as Directors of the Company for personal reasons. The resignations are effective as of April 1, 2021. The Board expressed its appreciation for Messrs. Girgenti’s and Rush’s many years of service to the Company. There were no disagreements between the Company and either of Messrs. Girgenti and/or Rush on any matters.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Vycor Medical, Inc.
By:	/s/ Peter C. Zachariou
Name:	Peter C. Zachariou
Title:	Chief Executive Officer
Dated: March 22, 2021